Clinical Trial: Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
Brief Summary: The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
Detailed Summary:
Sponsor: Lexicon Pharmaceuticals
Current Primary Outcome: Incidence of treatment-emergent adverse events [ Time Frame: 50 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Quality of Life measures [ Time Frame: Baseline and every 24 weeks ]
Original Secondary Outcome: Same as current
Information By: Lexicon Pharmaceuticals
Dates:
Date Received: December 31, 2013
Date Started: December 2013
Date Completion:
Last Updated: June 2, 2016
Last Verified: June 2016